Calgent Biotechnology
New Taipei City, Taiwan· Est.
Taiwan‑based Calgent develops oncology and immunology drugs using an integrated R&D platform to target unmet medical needs.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan‑based Calgent develops oncology and immunology drugs using an integrated R&D platform to target unmet medical needs.
OncologyImmunology
Technology Platform
An integrated R&D platform covering translational research, pharmacology, formulation, and clinical development to accelerate discovery and optimization of new molecular entities.
Opportunities
Strong demand for oncology and immunology therapies and a growing market for age‑related disease treatments provide ample partnership and licensing opportunities.
Risk Factors
Reliance on external financing, regulatory uncertainty, and intense competition in target therapeutic spaces could delay development and commercialization.
Competitive Landscape
Calgent competes with both global pharma and niche biotech firms in oncology and immunology, differentiating through its integrated R&D platform and robust IP portfolio.